CN113577073A - 基于阿拉莫林的药物治疗 - Google Patents
基于阿拉莫林的药物治疗 Download PDFInfo
- Publication number
- CN113577073A CN113577073A CN202111026050.3A CN202111026050A CN113577073A CN 113577073 A CN113577073 A CN 113577073A CN 202111026050 A CN202111026050 A CN 202111026050A CN 113577073 A CN113577073 A CN 113577073A
- Authority
- CN
- China
- Prior art keywords
- anamorelin
- patient
- patients
- cancer
- cachexia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045976P | 2014-09-04 | 2014-09-04 | |
| US62/045,976 | 2014-09-04 | ||
| CN201580059744.3A CN107205389A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580059744.3A Division CN107205389A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113577073A true CN113577073A (zh) | 2021-11-02 |
Family
ID=55436476
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111026050.3A Pending CN113577073A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
| CN201710646685.0A Pending CN107375285A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
| CN201580059744.3A Pending CN107205389A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
| CN202111027023.8A Pending CN113577074A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
| CN201811119404.7A Pending CN109172575A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710646685.0A Pending CN107375285A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
| CN201580059744.3A Pending CN107205389A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
| CN202111027023.8A Pending CN113577074A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
| CN201811119404.7A Pending CN109172575A (zh) | 2014-09-04 | 2015-08-28 | 基于阿拉莫林的药物治疗 |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159609A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Peanut formulations and uses thereof |
| GEAP201814459A (en) | 2014-09-04 | 2018-09-10 | Helsinn Healthcare Sa | Medical treatments based on anamorelin |
| US12433945B2 (en) | 2018-08-16 | 2025-10-07 | Société des Produits Nestlé S.A. | Peanut oral immunotherapy with maintenance dose |
| US12226448B2 (en) | 2018-12-20 | 2025-02-18 | Société des Produits Nestlé S.A. | Peanut oral immunotherapy dosing schedule for missed doses |
| CA3137295A1 (en) | 2019-05-10 | 2020-11-19 | Aimmune Therapeutics, Inc. | Methods for improving the quality of life of a patient with a peanut allergy |
| CN115569120A (zh) | 2019-08-30 | 2023-01-06 | 赫尔森保健股份公司 | 具有改善稳定性的阿拉莫林片剂的生产方法 |
| KR20220087427A (ko) | 2019-10-24 | 2022-06-24 | 도레이 카부시키가이샤 | 악액질의 치료제 또는 예방제 |
| JP2024534464A (ja) * | 2021-09-17 | 2024-09-20 | 小野薬品工業株式会社 | 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法 |
| WO2025004650A1 (ja) * | 2023-06-28 | 2025-01-02 | 日清オイリオグループ株式会社 | 中高年者の疲労感を軽減するための剤及び組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| ECSP993020A (es) | 1999-06-16 | 1999-08-12 | Terapia de combinacion para la fragilidad musculoesqueletica | |
| ECSP993021A (es) | 1999-06-16 | 1999-08-12 | Combinaciones terapeuticas para la fragilidad musculoesqueletica | |
| US20010020012A1 (en) | 2000-02-01 | 2001-09-06 | Andersen Maibritt Bansholm | Use of compounds for the regulation of food intake |
| EP1660117A2 (en) | 2003-08-06 | 2006-05-31 | Gastrotech Pharma A/S | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
| CN1863550A (zh) * | 2003-08-06 | 2006-11-15 | 加斯特罗泰克药物公司 | 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用 |
| KR20070010151A (ko) | 2004-03-30 | 2007-01-22 | 사파이어 세라퓨틱스, 인크. | 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법 |
| US7825138B2 (en) * | 2004-06-29 | 2010-11-02 | Helsinn Therapeutics (U.S.), Inc. | Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide |
| CA2677813A1 (en) * | 2007-02-13 | 2008-08-21 | Helsinn Therapeutics (U.S.), Inc. | Method of treating cell proliferative disorders using growth hormone secretagogues |
| TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| JO3353B1 (ar) * | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
| KR20150020602A (ko) * | 2012-05-25 | 2015-02-26 | 라퀄리아 파마 인코포레이티드 | 무산증 치료를 위한 그렐린 수용체 효능물질 |
| GEAP201814459A (en) | 2014-09-04 | 2018-09-10 | Helsinn Healthcare Sa | Medical treatments based on anamorelin |
-
2015
- 2015-08-28 GE GEAP201814459A patent/GEAP201814459A/en unknown
- 2015-08-28 MY MYPI2017700714A patent/MY187167A/en unknown
- 2015-08-28 SI SI201530994T patent/SI3188599T1/sl unknown
- 2015-08-28 CN CN202111026050.3A patent/CN113577073A/zh active Pending
- 2015-08-28 RS RS20191688A patent/RS59751B1/sr unknown
- 2015-08-28 PL PL15838548T patent/PL3188599T3/pl unknown
- 2015-08-28 BR BR112017003552A patent/BR112017003552A2/pt not_active Application Discontinuation
- 2015-08-28 UA UAA201702308A patent/UA120765C2/uk unknown
- 2015-08-28 ME MEP-2019-372A patent/ME03597B/me unknown
- 2015-08-28 KR KR1020217008765A patent/KR102307275B1/ko active Active
- 2015-08-28 HU HUE15838548A patent/HUE046894T2/hu unknown
- 2015-08-28 CA CA2959158A patent/CA2959158A1/en active Pending
- 2015-08-28 MX MX2017002825A patent/MX361741B/es active IP Right Grant
- 2015-08-28 PE PE2017000359A patent/PE20171109A1/es unknown
- 2015-08-28 LT LT15838548T patent/LT3188599T/lt unknown
- 2015-08-28 MA MA40607A patent/MA40607B1/fr unknown
- 2015-08-28 MD MDA20170025A patent/MD4710C1/ro active IP Right Grant
- 2015-08-28 EA EA201790352A patent/EA035578B1/ru unknown
- 2015-08-28 AU AU2015312231A patent/AU2015312231B2/en active Active
- 2015-08-28 CN CN201710646685.0A patent/CN107375285A/zh active Pending
- 2015-08-28 WO PCT/US2015/047435 patent/WO2016036598A1/en not_active Ceased
- 2015-08-28 US US14/839,038 patent/US9675600B2/en active Active
- 2015-08-28 SG SG11201701567UA patent/SG11201701567UA/en unknown
- 2015-08-28 JP JP2017512679A patent/JP6356907B2/ja active Active
- 2015-08-28 EP EP19183144.5A patent/EP3590338A3/en not_active Withdrawn
- 2015-08-28 DK DK15838548T patent/DK3188599T3/da active
- 2015-08-28 PT PT158385484T patent/PT3188599T/pt unknown
- 2015-08-28 KR KR1020187020062A patent/KR102234319B1/ko active Active
- 2015-08-28 CN CN201580059744.3A patent/CN107205389A/zh active Pending
- 2015-08-28 ES ES15838548T patent/ES2761777T3/es active Active
- 2015-08-28 CN CN202111027023.8A patent/CN113577074A/zh active Pending
- 2015-08-28 CN CN201811119404.7A patent/CN109172575A/zh active Pending
- 2015-08-28 HR HRP20192345TT patent/HRP20192345T1/hr unknown
- 2015-08-28 CR CR20170121A patent/CR20170121A/es unknown
- 2015-08-28 GE GEAP201514459A patent/GEP20186939B/en unknown
- 2015-08-28 TN TN2017000040A patent/TN2017000040A1/en unknown
- 2015-08-28 EP EP15838548.4A patent/EP3188599B1/en active Active
- 2015-08-28 AP AP2017009772A patent/AP2017009772A0/en unknown
- 2015-08-28 KR KR1020177008748A patent/KR101881264B1/ko active Active
- 2015-08-30 JO JOP/2015/0210A patent/JO3541B1/ar active
- 2015-09-01 TW TW104128838A patent/TWI639429B/zh active
- 2015-09-02 UY UY0001036286A patent/UY36286A/es not_active Application Discontinuation
- 2015-09-03 AR ARP150102818A patent/AR103118A1/es unknown
-
2017
- 2017-02-20 IL IL250692A patent/IL250692B/en active IP Right Grant
- 2017-03-02 PH PH12017500392A patent/PH12017500392B1/en unknown
- 2017-03-02 CL CL2017000494A patent/CL2017000494A1/es unknown
- 2017-03-03 SV SV2017005400A patent/SV2017005400A/es unknown
- 2017-03-03 DO DO2017000055A patent/DOP2017000055A/es unknown
- 2017-03-03 NI NI201700024A patent/NI201700024A/es unknown
- 2017-03-30 EC ECIEPI201719893A patent/ECSP17019893A/es unknown
- 2017-04-03 CO CONC2017/0003263A patent/CO2017003263A2/es unknown
- 2017-05-09 US US15/590,025 patent/US10278964B2/en active Active
-
2018
- 2018-06-14 JP JP2018113592A patent/JP6923486B2/ja active Active
-
2019
- 2019-02-14 US US16/275,669 patent/US10894041B2/en active Active
- 2019-12-16 CY CY20191101321T patent/CY1122746T1/el unknown
-
2020
- 2020-12-11 US US17/119,482 patent/US11723902B2/en active Active
-
2021
- 2021-02-26 JP JP2021029775A patent/JP7044918B2/ja active Active
-
2023
- 2023-06-22 US US18/212,720 patent/US20240024303A1/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| DAVID C CURROW等: "Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome" * |
| JOSE M GARCIA等: "Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study" * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11723902B2 (en) | Medical treatments based on anamorelin | |
| WO2019008571A1 (en) | SYSTEM AND METHOD SPECIFIC TO A SUBJECT FOR PREVENTING BODY ADAPTATION TO CHRONIC DISEASE TREATMENT | |
| Pae | Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting | |
| Battaglini et al. | A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy | |
| HK40020876A (en) | Medical treatments based on anamorelin | |
| HK1234959A1 (en) | Medical treatments based on anamorelin | |
| HK1234959B (en) | Medical treatments based on anamorelin | |
| OA18229A (en) | Medical treatments based on anamorelin. | |
| KR102481026B1 (ko) | 인터루킨 23의 항체를 포함하는 화학요법유발 말초신경병증의 예방 또는 치료용 약학적 조성물 | |
| NZ729673B2 (en) | Medical treatments based on anamorelin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |